324 related articles for article (PubMed ID: 17400453)
1. Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II.
Hidaka K; Kimura T; Tsuchiya Y; Kamiya M; Ruben AJ; Freire E; Hayashi Y; Kiso Y
Bioorg Med Chem Lett; 2007 Jun; 17(11):3048-52. PubMed ID: 17400453
[TBL] [Abstract][Full Text] [Related]
2. Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin.
Hidaka K; Kimura T; Ruben AJ; Uemura T; Kamiya M; Kiso A; Okamoto T; Tsuchiya Y; Hayashi Y; Freire E; Kiso Y
Bioorg Med Chem; 2008 Dec; 16(23):10049-60. PubMed ID: 18952439
[TBL] [Abstract][Full Text] [Related]
3. Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution.
Miura T; Hidaka K; Uemura T; Kashimoto K; Hori Y; Kawasaki Y; Ruben AJ; Freire E; Kimura T; Kiso Y
Bioorg Med Chem Lett; 2010 Aug; 20(16):4836-9. PubMed ID: 20634066
[TBL] [Abstract][Full Text] [Related]
4. Computational analysis of plasmepsin IV bound to an allophenylnorstatine inhibitor.
Gutiérrez-de-Terán H; Nervall M; Dunn BM; Clemente JC; Aqvist J
FEBS Lett; 2006 Oct; 580(25):5910-6. PubMed ID: 17045991
[TBL] [Abstract][Full Text] [Related]
5. Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases.
Abdel-Rahman HM; Kimura T; Hidaka K; Kiso A; Nezami A; Freire E; Hayashi Y; Kiso Y
Biol Chem; 2004 Nov; 385(11):1035-9. PubMed ID: 15576323
[TBL] [Abstract][Full Text] [Related]
6. Exploring the flap pocket of the antimalarial target plasmepsin II: the "55 % rule" applied to enzymes.
Zürcher M; Gottschalk T; Meyer S; Bur D; Diederich F
ChemMedChem; 2008 Feb; 3(2):237-40. PubMed ID: 17918177
[No Abstract] [Full Text] [Related]
7. Structure of the aspartic protease plasmepsin 4 from the malarial parasite Plasmodium malariae bound to an allophenylnorstatine-based inhibitor.
Clemente JC; Govindasamy L; Madabushi A; Fisher SZ; Moose RE; Yowell CA; Hidaka K; Kimura T; Hayashi Y; Kiso Y; Agbandje-McKenna M; Dame JB; Dunn BM; McKenna R
Acta Crystallogr D Biol Crystallogr; 2006 Mar; 62(Pt 3):246-52. PubMed ID: 16510971
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of allophenylnorstatine-based inhibitors of plasmepsin II, an antimalarial target.
Nezami A; Luque I; Kimura T; Kiso Y; Freire E
Biochemistry; 2002 Feb; 41(7):2273-80. PubMed ID: 11841219
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, biological evaluation, and modeling studies of inhibitors aimed at the malarial proteases plasmepsins I and II.
Muthas D; Nöteberg D; Sabnis YA; Hamelink E; Vrang L; Samuelsson B; Karlén A; Hallberg A
Bioorg Med Chem; 2005 Sep; 13(18):5371-90. PubMed ID: 16054370
[TBL] [Abstract][Full Text] [Related]
10. Search for substrate-based inhibitors fitting the S2' space of malarial aspartic protease plasmepsin II.
Kiso A; Hidaka K; Kimura T; Hayashi Y; Nezami A; Freire E; Kiso Y
J Pept Sci; 2004 Nov; 10(11):641-7. PubMed ID: 15568678
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of plasmepsin I and plasmepsin II inhibitors with activity in Plasmodium falciparum-infected cultured human erythrocytes.
Nöteberg D; Hamelink E; Hultén J; Wahlgren M; Vrang L; Samuelsson B; Hallberg A
J Med Chem; 2003 Feb; 46(5):734-46. PubMed ID: 12593654
[TBL] [Abstract][Full Text] [Related]
12. Identification of potent inhibitors of Plasmodium falciparum plasmepsin II from an encoded statine combinatorial library.
Carroll CD; Patel H; Johnson TO; Guo T; Orlowski M; He ZM; Cavallaro CL; Guo J; Oksman A; Gluzman IY; Connelly J; Chelsky D; Goldberg DE; Dolle RE
Bioorg Med Chem Lett; 1998 Sep; 8(17):2315-20. PubMed ID: 9873534
[TBL] [Abstract][Full Text] [Related]
13. Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV.
Ersmark K; Nervall M; Gutiérrez-de-Terán H; Hamelink E; Janka LK; Clemente JC; Dunn BM; Gogoll A; Samuelsson B; Qvist J; Hallberg A
Bioorg Med Chem; 2006 Apr; 14(7):2197-208. PubMed ID: 16307884
[TBL] [Abstract][Full Text] [Related]
14. Optimization of plasmepsin inhibitor by focusing on similar structural feature with chloroquine to avoid drug-resistant mechanism of Plasmodium falciparum.
Miura T; Hidaka K; Azai Y; Kashimoto K; Kawasaki Y; Chen SE; de Freitas RF; Freire E; Kiso Y
Bioorg Med Chem Lett; 2014 Apr; 24(7):1698-701. PubMed ID: 24631188
[TBL] [Abstract][Full Text] [Related]
15. Identification of acridinyl hydrazides as potent aspartic protease inhibitors.
Azim MK; Ahmed W; Khan IA; Rao NA; Khan KM
Bioorg Med Chem Lett; 2008 May; 18(9):3011-5. PubMed ID: 18417344
[TBL] [Abstract][Full Text] [Related]
16. Achiral, cheap, and potent inhibitors of Plasmepsins I, II, and IV.
Boss C; Corminboeuf O; Grisostomi C; Meyer S; Jones AF; Prade L; Binkert C; Fischli W; Weller T; Bur D
ChemMedChem; 2006 Dec; 1(12):1341-5. PubMed ID: 17091526
[No Abstract] [Full Text] [Related]
17. High-speed optimization of inhibitors of the malarial proteases plasmepsin I and II.
Nöteberg D; Schaal W; Hamelink E; Vrang L; Larhed M
J Comb Chem; 2003; 5(4):456-64. PubMed ID: 12857114
[TBL] [Abstract][Full Text] [Related]
18. alpha-Substituted norstatines as the transition-state mimic in inhibitors of multiple digestive vacuole malaria aspartic proteases.
Orrling KM; Marzahn MR; Gutiérrez-de-Terán H; Aqvist J; Dunn BM; Larhed M
Bioorg Med Chem; 2009 Aug; 17(16):5933-49. PubMed ID: 19635672
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and activity of tetrapeptidic HTLV-I protease inhibitors possessing different P3-cap moieties.
Zhang M; Nguyen JT; Kumada HO; Kimura T; Cheng M; Hayashi Y; Kiso Y
Bioorg Med Chem; 2008 May; 16(10):5795-802. PubMed ID: 18400502
[TBL] [Abstract][Full Text] [Related]
20. Plasmepsin II inhibition and antiplasmodial activity of Primaquine-Statine 'double-drugs'.
Romeo S; Dell'Agli M; Parapini S; Rizzi L; Galli G; Mondani M; Sparatore A; Taramelli D; Bosisio E
Bioorg Med Chem Lett; 2004 Jun; 14(11):2931-4. PubMed ID: 15125962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
